Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03725098
Other study ID # ETC 2018-005
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 1, 2019
Est. completion date June 28, 2019

Study information

Verified date January 2020
Source Biom'Up SA
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the performance of HEMOBLAST™ compared to FLOSEAL in cardiothoracic operations.


Description:

A maximum of 104 subjects will be enrolled across a maximum of 5 study sites in the United States.

The estimated duration of the study is approximately 8 months from the time of first subject enrollment to the last subject enrollment. Enrollment occurs intraoperatively after confirmation of the intraoperative eligibility criteria. Subjects will undergo intraoperative performance assessments and then will be discontinued from the study after completion of the intraoperative visit.


Recruitment information / eligibility

Status Completed
Enrollment 105
Est. completion date June 28, 2019
Est. primary completion date June 28, 2019
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Preoperative Inclusion Criteria

- Subject is undergoing a non-emergent cardiothoracic surgery; and

- Subject or an authorized legal representative is willing and able to give prior written informed consent for study participation.

Preoperative Exclusion Criteria

- Subject has a known sensitivity or allergy to bovine and/or porcine substance(s) or any other component(s) of the hemostatic agent;

- Subject has religious or other objections to porcine or bovine components; and

- Subject is not appropriate for inclusion in the clinical study, per the medical opinion of the Investigator.

Intraoperative Inclusion Criteria

- Subject does not have an active or suspected infection at the surgical site;

- Subject in whom the Investigator is able to identify a Target Bleeding Site (TBS) for which any applicable conventional means for hemostasis are ineffective or impractical; and

- Subject has a TBS with minimal, mild, or moderate bleeding

Study Design


Related Conditions & MeSH terms


Intervention

Device:
HEMOBLAST Bellows
The HEMOBLAST™ Bellows hemostatic agent consists of a bellows pre-loaded with 1.65g of powder composed of collagen, chondroitin sulfate, and thrombin (1500 IU). HEMOBLAST™ Bellows is indicated in surgical procedures as an adjunct to hemostasis when control of minimal, mild, and moderate bleeding by conventional procedures is ineffective or impractical, except in neurosurgical, ophthalmic, and urological procedures.
FLOSEAL
The FLOSEAL Matrix consists of a bovine-derived Gelatin Matrix component, a human-derived Thrombin component, applicator tips, and several mixing accessories. FLOSEAL is indicated in surgical procedures (other than ophthalmic) as an adjunct to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical.

Locations

Country Name City State
United States Kaiser Permanente Moanalua Medical Center Honolulu Hawaii
United States Houston Methodist Houston Texas
United States University of California Los Angeles Los Angeles California
United States Ochsner Clinic Foundation New Orleans Louisiana

Sponsors (1)

Lead Sponsor Collaborator
Biom'Up SA

Country where clinical trial is conducted

United States, 

References & Publications (1)

Dang NC, Ardehali A, Bruckner BA, Parrino PE, Gillen DL, Hoffman RW, Spotnitz R, Cavoores S, Shorn IJ, Manson RJ, Spotnitz WD. Prospective, multicenter, randomized, controlled trial evaluating the performance of a novel combination powder vs hemostatic matrix in cardiothoracic operations. J Card Surg. 2019 Nov 25. doi: 10.1111/jocs.14376. [Epub ahead of print] — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary 3 Minute Hemostasis - Hemostatic Success (Yes/no) at 3 Minutes The primary endpoint of this study is the superiority of HEMOBLAST™ relative to FLOSEAL for the proportion of subjects reaching hemostasis within 3 minutes. Intraoperative
Secondary 5 Minute Hemostasis - Hemostatic Success (Yes/no) at 5 Minutes The secondary endpoint of this study is non-inferiority of HEMOBLAST™ relative to FLOSEAL for the proportion of subjects reaching hemostasis within 5 minutes. Intraoperative
See also
  Status Clinical Trial Phase
Recruiting NCT05968456 - Complexity and Frailty in Cardiothoracic and Vascular Anesthesia (CAfCA). Prospective Multicentric Observational Study
Enrolling by invitation NCT04065919 - Evaluation of Liposomal Bupivacaine Compared to Usual Care and Its Effects on Pain for Cardiac Surgery Phase 4
Not yet recruiting NCT05079724 - Acute Kidney Injury After Cardiac Surgery
Completed NCT01847859 - Pocket-size Ultrasound by Nurses in Cardiothoracic Post-operative Patients N/A
Terminated NCT01897519 - A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Surgery Phase 2
Recruiting NCT02863250 - Australian and New Zealand Massive Transfusion Registry
Terminated NCT00075179 - Natrecor in Pulmonary Hypertension Phase 4
Recruiting NCT02029534 - Intensive Statin Therapy Effect on Post-Operative Atrial Fibrillation (POAF) Phase 4
Recruiting NCT03639519 - A Trial to Assess the Impact of Ascorbic Acid on Cardiac Surgeries Outcomes and Complications'' Phase 4